Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + Pucotenlimab vs Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06976190Phase 3Recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- May 2025
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of becotatug vedotin and pucotenlimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Lepu Biopharma Co., Ltd. Primary endpoints: Progression Free Survival as assessed by BIRC up to 33 months and Overall Survival up to 48 months. Started May 2025; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06976190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976190.